The present study investigates the interrelated pathophysiology of depression and Alzheimer’s disease (AD), with the objective of elucidating common underlying mechanisms.
Objective:
Our objective is to identify previously undiscovered biogenic compounds from the NuBBE database that specifically interact with GluR3. This study examines the bidirectional association between depression and AD, specifically focusing on the role of depression as a risk factor in the onset and progression of the disease.
Methods:
In this study, we utilize pharmacokinetics, homology modeling, and molecular docking-based virtual screening techniques to examine the GluR3 AMPA receptor subunit.
Results:
The compounds, namely ZINC000002558953, ZINC000001228056, ZINC000000187911, ZINC000003954487, and ZINC000002040988, exhibited favorable pharmacokinetic profiles and drug-like characteristics, displaying high binding affinities to the GluR3 binding pocket.
Conclusions:
These findings suggest that targeting GluR3 could hold promise for the development of therapies for depression and AD. Further validation through in vitro, in vivo, and clinical studies is necessary to explore the potential of these compounds as lead candidates for potent and selective GluR3 inhibitors. The shared molecular mechanisms between depression and AD provide an opportunity for novel treatment approaches that address both conditions simultaneously.
BainsN, AbdijadidS (2022) Major depressive disorder. In StatPearls [Internet]StatPearls Publishing.
3.
XiaC-Y, HeJ, DuL-D, YanY, LianW-W, XuJ-K, ZhangW-K (2021) Targeting the dysfunction of glutamate receptors for the development of novel antidepressants. Pharmacol Ther226, 107875.
4.
OwnbyRL, CroccoE, AcevedoA, JohnV, LoewensteinD (2006) Depression and risk for Alzheimer disease: Systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry63, 530–538.
5.
DinizBS, ButtersMA, AlbertSM, DewMA, ReynoldsCF3rd (2013) Late-life depression and risk of vascular dementia and Alzheimer’s disease: Systematic review and meta-analysis of community-based cohort studies. Br J Psychiatry202, 329–335.
6.
CaraciF, CopaniA, NicolettiF, DragoF (2010) Depression and Alzheimer’s disease: Neurobiological links and common pharmacological targets. Eur J Pharmacol626, 64–71.
7.
HorH, TaftiM (2017) Chapter 6 - Genetics of normal human sleep. In Principles and Practice of Sleep Medicine (Sixth Edition),
KrygerM,
RothT,
DementWC, eds. Elsevier, pp. 56–61.e54.
8.
RoiserJP, SahakianBJ (2013) Hot and cold cognition in depression. CNS Spectr18, 139–149.
OnaolapoAY, OnaolapoOJ (2021) Glutamate and depression: Reflecting a deepening knowledge of the gut and brain effects of a ubiquitous molecule. World J Psychiatry11, 297–315.
SuzukiK, MonteggiaLM (2020) Chapter Three - The role of eEF2 kinase in the rapid antidepressant actions of ketamine. In Advances in Pharmacology,
DumanRS,
KrystalJH, eds. Academic Press, pp. 79–99.
13.
MitchellND, BakerGB (2010) An update on the role of glutamate in the pathophysiology of depression. Acta Psychiatr Scand122, 192–210.
14.
NewmanDJ, CraggGM (2016) Natural products as sources of new drugs from 1981 to 2014. J Nat Prod79, 629–661.
15.
JolyCA, RodriguesRR, MetzgerJP, HaddadCF, VerdadeLM, OliveiraMC, BolzaniVS (2010) Biodiversity conservation research, training, and policy in São Paulo. Science328, 1358–1359.
16.
De LucaV, SalimV, AtsumiSM, YuF (2012) Mining the biodiversity of plants: A revolution in the making. Science336, 1658–1661.
17.
BrodieJ, PostE, LauranceWF (2012) Climate change and tropical biodiversity: A new focus. Trends Ecol Evol27, 145–150.
BanerjeeP, EckertAO, SchreyAK, PreissnerR (2018) ProTox-II: A webserver for the prediction of toxicity of chemicals. Nucleic Acids Res46, W257–W263.
20.
MistryJ, ChuguranskyS, WilliamsL, QureshiM, SalazarGA, SonnhammerELL, TosattoSCE, PaladinL, RajS, RichardsonLJ, FinnRD, BatemanA (2021) Pfam: The protein families database in 2021. Nucleic Acids Res49, D412–D419.
21.
LetunicI, KhedkarS, BorkP (2021) SMART: Recent updates, new developments and status in 2020. Nucleic Acids Res49, D458–d460.
22.
WaterhouseA, BertoniM, BienertS, StuderG, TaurielloG, GumiennyR, HeerFT, de BeerTAP, RempferC, BordoliL, LeporeR, SchwedeT (2018) SWISS-MODEL: Homology modelling of protein structures and complexes. Nucleic Acids Res46, W296–w303.
23.
WuG, RobertsonDH, Brooks IIICL, ViethM (2003) Detailed analysis of grid-based molecular docking: A case study of CDOCKER—A CHARMm-based MD docking algorithm. J Comput Chem24, 1549–1562.
24.
KelleyLA, MezulisS, YatesCM, WassMN, SternbergMJE (2015) The Phyre2 web portal for protein modeling, prediction and analysis. Nat Protoc10, 845–858.
25.
PieperU, EswarN, DavisFP, BrabergH, MadhusudhanMS, RossiA, Marti-RenomM, KarchinR, WebbBM, EramianD, ShenM-Y, KellyL, MeloF, SaliA (2006) MODBASE: A database of annotated comparative protein structure models and associated resources. Nucleic Acids Res34, D291–D295.
26.
ZrieqR, AhmadI, SnoussiM, NoumiE, IritiM, AlgahtaniFD, PatelH, SaeedM, TasleemM, SulaimanS, AouadiK, KadriA (2021) Tomatidine and patchouli alcohol as inhibitors of SARS-CoV-2 enzymes (3CLpro, PLpro and NSP15) by molecular docking and molecular dynamics simulations. Int J Mol Sci22, 10693.
27.
TasleemM, AlrehailyA, AlmeleebiaTM, AlshahraniMY, AhmadI, AsiriM, AlabdallahNM, SaeedM (2021) Investigation of antidepressant properties of yohimbine by employing structure-based computational assessments. Curr Issues Mol Biol43, 1805–1827.
28.
TasleemM, El-SayedA-AAA, HusseinWM, AlrehailyA (2023) Bioremediation of chromium-contaminated groundwater using chromate reductase from Pseudomonas putida: An in silico approach. Water15, 150.
29.
ZhaoY, ChenS, SwensenAC, QianW-J, GouauxE (2019) Architecture and subunit arrangement of native AMPA receptors elucidated by cryo-EM. Science364, 355–362.
30.
MistryJ, ChuguranskyS, WilliamsL, QureshiM, Salazar GustavoA, SonnhammerELL, TosattoSCE, PaladinL, RajS, RichardsonLJ, FinnRD, BatemanA (2020) Pfam: The protein families database in 2021. Nucleic Acids Res49, D412–D419.
31.
UmarAB, UzairuA, ShallangwaGA, UbaS (2020) Design of potential anti-melanoma agents against SK-MEL-5 cell line using QSAR modeling and molecular docking methods. SN Appl Sci2, 815.
32.
AttiqueSA, HassanM, UsmanM, AtifRM, MahboobS, Al-GhanimKA, BilalM, NawazMZ (2019) A molecular docking approach to evaluate the pharmacological properties of natural and synthetic treatment candidates for use against hypertension. Int J Environ Res Public Health16, 923.
33.
AbdullahiM, AdenijiSE (2020) In-silico molecular docking and ADME/pharmacokinetic prediction studies of some novel carboxamide derivatives as anti-tubercular agents. Chem Africa3, 989–1000.
34.
PardridgeWM (2005) The blood-brain barrier: Bottleneck in brain drug development. NeuroRx2, 3–14.
35.
PardridgeWM (2012) Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab32, 1959–1972.
36.
Da SettimoF, PrimofioreG, Da SettimoA, La MottaC, TalianiS, SimoriniF, NovellinoE, GrecoG, LavecchiaA, BoldriniE (2001) [1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: A new class of selective aldose reductase inhibitors. J Med Chem44, 4359–4369.
37.
WesselMD, JursPC, TolanJW, MuskalSM (1998) Prediction of human intestinal absorption of drug compounds from molecular structure. J Chem Inf Comput Sci38, 726–735.
38.
AlamS, KhanF (2019) 3D-QSAR, docking, ADME/Tox studies on flavone analogs reveal anticancer activity through tankyrase inhibition. Sci Rep9, 5414.
39.
SharathAK, HaqueN, PrabhuNP (2020) Spontaneous lid closure and substrate-induced lid opening dynamics of human pancreatic lipase-related protein 2: A computational study. J Mol Struct1217, 128365.
40.
ZhangH, ZhangL, GaoC, YuR, KangC (2021) Pharmacophore screening, molecular docking, ADMET prediction and MD simulations for identification of ALK and MEK potential dual inhibitors. J Mol Struct1245, 131066.
41.
PillaiLS, NairBR (2018) Molecular docking studies using sinigrin and tamoxifen. J Pharmacogn Phytochem7, 3217–3221.
42.
KuryatovA, LaubeB, BetzH, KuhseJ (1994) Mutational analysis of the glycine-binding site of the NMDA receptor: Structural similarity with bacterial amino acid-binding proteins. Neuron12, 1291–1300.
43.
JayaramB, DhingraP, MishraA, KaushikR, MukherjeeG, SinghA, ShekharS (2014) Bhageerath-H: A homology/ab initio hybrid server for predicting tertiary structures of monomeric soluble proteins. BMC Bioinform15 Suppl 16, S7.
44.
FiserA (2010) Template-based protein structure modeling. Methods Mol Biol673,, 73–94.
45.
MeloF, SaliA (2007) Fold assessment for comparative protein structure modeling. Protein Sci16, 2412–2426.
46.
ZhangY, SkolnickJ (2004) Scoring function for automated assessment of protein structure template quality. Proteins57, 702–710.
47.
CozzettoD, KryshtafovychA, CerianiM, TramontanoA (2007) Assessment of predictions in the model quality assessment category. Proteins69, 175–183.
48.
LaskowskiRA, MacArthurMW, MossDS, ThorntonJM (1993) PROCHECK: A program to check the stereochemical quality of protein structures. J Appl Crystallogr26, 283–291.
49.
SinghA, KaushikR, JayaramB (2018) Quality assessment of protein tertiary structures: Past, present, and future. Bioinformatics: Sequences, Structures, Phylogeny,
ShankerA, ed. Springer, Singapore, pp. 271–288.
50.
ColovosC, YeatesTO (1993) Verification of protein structures: Patterns of nonbonded atomic interactions. Protein Sci2, 1511–1519.
51.
UzielaK, ShuN, WallnerB, ElofssonA (2016) ProQ3: Improved model quality assessments using Rosetta energy terms. Sci Rep6, 33509.
52.
HooftRW, SanderC, VriendG (1997) Objectively judging the quality of a protein structure from a Ramachandran plot. Comput Appl Biosci13, 425–430.
53.
HollingsworthSA, KarplusPA (2010) A fresh look at the Ramachandran plot and the occurrence of standard structures in proteins. Biomol Concepts1, 271–283.
54.
RavalK, GanatraT (2022) Basics, types and applications of molecular docking: A review. IP Int J Compr Adv Pharmacol7, 12–16.
55.
PanigrahiSK (2008) Strong and weak hydrogen bonds in protein-ligand complexes of kinases: A comparative study. Amino Acids34, 617–633.
56.
DavisAM, TeagueSJ (1999) Hydrogen bonding, hydrophobic interactions, and failure of the rigid receptor hypothesis. Angew Chem Int Ed Engl38, 736–749.
57.
EspositoZ, BelliL, TonioloS, SancesarioG, BianconiC, MartoranaA (2013) Amyloid beta, glutamate, excitotoxicity in Alzheimer’s disease: Are we on the right track?CNS Neurosci Ther19, 549–555.
58.
KinneyJW, BemillerSM, MurtishawAS, LeisgangAM, SalazarAM, LambBT (2018) Inflammation as a central mechanism in Alzheimer’s disease. Alzheimers Dement (N Y)4, 575–590.
59.
SimicG, Babic LekoM, WrayS, HarringtonC, DelalleI, Jovanov-MilosevicN, BazadonaD, BueeL, de SilvaR, Di GiovanniG, WischikC, HofPR (2016) Tau protein hyperphosphorylation and aggregation in Alzheimer’s disease and other tauopathies, and possible neuroprotective strategies. Biomolecules6, 6.
60.
MandlikDS, MandlikSK, SA (2022) Therapeutic implications of glycogen synthase kinase-3beta in Alzheimer’s disease: A novel therapeutic target. Int J Neurosci, doi: 10.1080/00207454.2022.2130297.
61.
KessingLV, AndersenPK (2004) Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder?J Neurol Neurosurg Psychiatry75, 1662–1666.
